AIM ImmunoTech Inc. — Director's Dealing 2012

Apr 16, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HEMISPHERX BIOPHARMA INC (HEB)
CIK: 0000946644
Period of Report: 2012-04-13

Reporting Person: STRAYER DAVID R (Medical Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2012-04-13	Options to buy Common Stock	$4.03	J	10000	Acquired	2022-04-13	Common Stock (10000)	Direct

Footnotes

F1: Replacement of expired option to purchase common stock.